BioSpace News Archive

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today published its financial results for the quarter ended June 30, 2023 and provided a business update.

Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc., completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc.

In response to the opioid crisis, researchers at Hospital for Special Surgery (HSS) are looking for alternate ways to reduce pain after orthopedic procedures.

Biophytis SA announced that it has received feedback from the European Medicines Agency and the Food and Drug Administration enabling it to plan the next regulatory steps for its COVA project dedicated to the development of Sarconeos for severe forms of Covid-19.

Promore Pharma AB announced that the company has entered into an agreement with Erik Penser Bank to act as liquidity provider for the Promore Pharma share starting 21 August 2023.

Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the IND for SB221 (NCT05756907), the Phase 1b/2a clinical trial of SON-1010(IL12-FHAB) in combination with Roche’s anti-PD-L1 checkpoint inhibitor, atezolizumab, has been accepted, and the study can begin in the US for the treatment of PROC.

Comera Life Sciences Holdings, Inc. today announced the peer-reviewed publication of preclinical data in the Journal of Pharmaceutical Sciences, which provide further evidence of caffeine’s viscosity reducing capabilities and support further development of caffeine as a viscosity reducing agent for subcutaneous (SQ) formulations of monoclonal antibodies.

RVL Pharmaceuticals plc today announced that it has entered into definitive agreements for the purchase and sale of 11,870,846 of its ordinary shares.

Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK ® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis.

Sparrow Pharmaceuticals today announced the first patient has elected to enroll in the open-label extension (OLE) phase of the RESCUE trial, a phase 2 clinical trial of SPI-62.